Ariad Pharm Inc (ARIA) 13.41 $ARIA
Watch for Ariad Pharmaceuticals to Potentially Pullback After Gaining 6.52% Yesterday
Comtex SmarTrend(R) - Tue Sep 20, 12:53PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $12.13 to a high of $13.05. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $12.20 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 13.41 (+0.51)
ARIAD Announces Ponatinib Data Presentations at European School of Haematology Annual John Goldman Conference on Chronic Myeloid Leukemia
BusinessWire - Thu Sep 15, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced several data presentations on Iclusig(R) (ponatinib) that will take place at the 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy being held in Houston, September 15 to 18, 2016. A total of eight abstracts will be presented, including two oral presentations. The schedule and abstract information are listed below:
ARIA: 13.41 (+0.51)
Ariad Pharmaceuticals Shares Up 36.5% Since SmarTrend's Buy Recommendation (ARIA)
Comtex SmarTrend(R) - Thu Sep 15, 12:45AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 2 months, Ariad Pharmaceuticals has returned 36.52% as of today's recent price of $11.01.
ARIA: 13.41 (+0.51)
Ariad Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 4.80%
Comtex SmarTrend(R) - Wed Sep 14, 1:23PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $10.67 to a high of $11.29. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $10.73 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 13.41 (+0.51)
Ariad Pharmaceuticals Shares Up 28.1% Since SmarTrend's Buy Recommendation (ARIA)
Comtex SmarTrend(R) - Wed Sep 07, 1:52PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 2 months, Ariad Pharmaceuticals has returned 28.08% as of today's recent price of $10.33.
ARIA: 13.41 (+0.51)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 81.70 (-0.08), ALXN: 130.36 (-1.37), MYL: 41.91 (+0.65), AMGN: 173.85 (+0.47), ARIA: 13.41 (+0.51), RIGL: 3.48 (-0.02), REGN: 406.52 (+0.28)
ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:24AM CDT
ARIAD Pharmaceuticals (ARIA) completed the rolling submission of the new drug application for brigatinib, to the FDA.
ANIP: 65.12 (+0.28), GERN: 2.25 (+0.20), PFE: 34.28 (+0.47), ARIA: 13.41 (+0.51)
Shares of ARIA Up 29.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 31, 1:12AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 1 month, Ariad Pharmaceuticals has returned 29.32% as of today's recent price of $10.43.
ARIA: 13.41 (+0.51)
After Yesterday's Rally of 1.52% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Aug 30, 4:11PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $10.27 to a high of $10.45. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $10.39 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 13.41 (+0.51)
ARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration
BusinessWire - Tue Aug 30, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.S. Food and Drug Administration (FDA). ARIAD is seeking U.S. marketing approval of brigatinib for patients with metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC) who are resistant or intolerant to crizotinib. The Company is seeking accelerated approval for brigatinib from the FDA and has requested a priority review of the application, which, if granted, would allow for approval of brigatinib eight months after the NDA submission, as opposed to 12 months for a standard review.
ARIA: 13.41 (+0.51)
ARIAD to Present at the Morgan Stanley Global Healthcare Conference
BusinessWire - Mon Aug 29, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Morgan Stanley Global Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company's business on Monday, September 12, 2016 at 2:50 p.m. (ET).
ARIA: 13.41 (+0.51), MS: 31.92 (+0.22)
SmarTrend Watching for Potential Pullback in Shares of Ariad Pharmaceuticals After 1.32% Gain
Comtex SmarTrend(R) - Wed Aug 24, 2:35PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $10.51 to a high of $10.85. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $10.82 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 13.41 (+0.51)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 30.1% (ARIA)
Comtex SmarTrend(R) - Tue Aug 23, 1:16PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 1 month, Ariad Pharmaceuticals has returned 30.07% as of today's recent price of $10.49.
ARIA: 13.41 (+0.51)
32.2% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Tue Aug 16, 12:44AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 3 weeks, Ariad Pharmaceuticals has returned 32.18% as of today's recent price of $10.66.
ARIA: 13.41 (+0.51)
Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 2.30% Rise
Comtex SmarTrend(R) - Tue Aug 09, 3:40PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $9.92 to a high of $10.35. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $10.18 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 13.41 (+0.51)
Ariad Pharmaceuticals Up 24.5% Since SmarTrend Uptrend Call (ARIA)
Comtex SmarTrend(R) - Mon Aug 08, 1:46PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 2 weeks, Ariad Pharmaceuticals has returned 24.49% as of today's recent price of $10.04.
ARIA: 13.41 (+0.51)
Potash Corporation of Saskatchewan trade offers a 38% return in 134 days, or find similar option trades on American Airlines, Wynn Resorts, Monsanto Company, and Ariad Pharmaceuticals
PR Newswire - Fri Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAL, ARIA, MON, POT, and WYNN.
MON: 104.36 (+1.48), POT: 16.09 (+0.15), WYNN: 103.00 (-0.49), AAL: 34.67 (-0.48), ARIA: 13.41 (+0.51)
4 Biotech Stocks Poised to Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 3:18PM CDT
Notwithstanding the sector declines, things appear far better now than they did a quarter ago for the biotech sector.
BIIB: 312.00 (+4.95), BMRN: 97.57 (-0.38), GILD: 81.70 (-0.08), AMGN: 173.85 (+0.47), ABBV: 64.10 (+0.82), ARIA: 13.41 (+0.51), AEGN: 18.27 (+0.37)
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Mon Aug 01, 3:02PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib). As a result of the second tranche payment, under the terms of the ARIAD Royalty Agreement, PDL's royalty percentage will increase to 5.0% of the U.S. and European net revenues of Iclusig and 5.0% of the payments ARIAD receives elsewhere in the world until December 31, 2018 (subject to agreed-upon annual maximum payments). Beginning January 1, 2019 and thereafter, the royalty rate will increase to 6.5% in all jurisdictions and continue until December 31, 2033, subject to a put option of PDL upon the occurrence of specified events and a call option of ARIAD.
ARIA: 13.41 (+0.51), PDLI: 3.36 (+0.13)
Watch for Ariad Pharmaceuticals to Potentially Pullback After Gaining 6.52% Yesterday
Comtex SmarTrend(R) - Tue Sep 20, 12:53PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $12.13 to a high of $13.05. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $12.20 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 13.41 (+0.51)
ARIAD Announces Ponatinib Data Presentations at European School of Haematology Annual John Goldman Conference on Chronic Myeloid Leukemia
BusinessWire - Thu Sep 15, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced several data presentations on Iclusig(R) (ponatinib) that will take place at the 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy being held in Houston, September 15 to 18, 2016. A total of eight abstracts will be presented, including two oral presentations. The schedule and abstract information are listed below:
ARIA: 13.41 (+0.51)
Ariad Pharmaceuticals Shares Up 36.5% Since SmarTrend's Buy Recommendation (ARIA)
Comtex SmarTrend(R) - Thu Sep 15, 12:45AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 2 months, Ariad Pharmaceuticals has returned 36.52% as of today's recent price of $11.01.
ARIA: 13.41 (+0.51)
Ariad Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 4.80%
Comtex SmarTrend(R) - Wed Sep 14, 1:23PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $10.67 to a high of $11.29. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $10.73 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 13.41 (+0.51)
Ariad Pharmaceuticals Shares Up 28.1% Since SmarTrend's Buy Recommendation (ARIA)
Comtex SmarTrend(R) - Wed Sep 07, 1:52PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 2 months, Ariad Pharmaceuticals has returned 28.08% as of today's recent price of $10.33.
ARIA: 13.41 (+0.51)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 81.70 (-0.08), ALXN: 130.36 (-1.37), MYL: 41.91 (+0.65), AMGN: 173.85 (+0.47), ARIA: 13.41 (+0.51), RIGL: 3.48 (-0.02), REGN: 406.52 (+0.28)
ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:24AM CDT
ARIAD Pharmaceuticals (ARIA) completed the rolling submission of the new drug application for brigatinib, to the FDA.
ANIP: 65.12 (+0.28), GERN: 2.25 (+0.20), PFE: 34.28 (+0.47), ARIA: 13.41 (+0.51)
Shares of ARIA Up 29.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 31, 1:12AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 1 month, Ariad Pharmaceuticals has returned 29.32% as of today's recent price of $10.43.
ARIA: 13.41 (+0.51)
After Yesterday's Rally of 1.52% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Aug 30, 4:11PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $10.27 to a high of $10.45. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $10.39 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 13.41 (+0.51)
ARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration
BusinessWire - Tue Aug 30, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.S. Food and Drug Administration (FDA). ARIAD is seeking U.S. marketing approval of brigatinib for patients with metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC) who are resistant or intolerant to crizotinib. The Company is seeking accelerated approval for brigatinib from the FDA and has requested a priority review of the application, which, if granted, would allow for approval of brigatinib eight months after the NDA submission, as opposed to 12 months for a standard review.
ARIA: 13.41 (+0.51)
ARIAD to Present at the Morgan Stanley Global Healthcare Conference
BusinessWire - Mon Aug 29, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Morgan Stanley Global Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company's business on Monday, September 12, 2016 at 2:50 p.m. (ET).
ARIA: 13.41 (+0.51), MS: 31.92 (+0.22)
SmarTrend Watching for Potential Pullback in Shares of Ariad Pharmaceuticals After 1.32% Gain
Comtex SmarTrend(R) - Wed Aug 24, 2:35PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $10.51 to a high of $10.85. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $10.82 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 13.41 (+0.51)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 30.1% (ARIA)
Comtex SmarTrend(R) - Tue Aug 23, 1:16PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 1 month, Ariad Pharmaceuticals has returned 30.07% as of today's recent price of $10.49.
ARIA: 13.41 (+0.51)
32.2% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Tue Aug 16, 12:44AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 3 weeks, Ariad Pharmaceuticals has returned 32.18% as of today's recent price of $10.66.
ARIA: 13.41 (+0.51)
Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 2.30% Rise
Comtex SmarTrend(R) - Tue Aug 09, 3:40PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $9.92 to a high of $10.35. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $10.18 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 13.41 (+0.51)
Ariad Pharmaceuticals Up 24.5% Since SmarTrend Uptrend Call (ARIA)
Comtex SmarTrend(R) - Mon Aug 08, 1:46PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 2 weeks, Ariad Pharmaceuticals has returned 24.49% as of today's recent price of $10.04.
ARIA: 13.41 (+0.51)
Potash Corporation of Saskatchewan trade offers a 38% return in 134 days, or find similar option trades on American Airlines, Wynn Resorts, Monsanto Company, and Ariad Pharmaceuticals
PR Newswire - Fri Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAL, ARIA, MON, POT, and WYNN.
MON: 104.36 (+1.48), POT: 16.09 (+0.15), WYNN: 103.00 (-0.49), AAL: 34.67 (-0.48), ARIA: 13.41 (+0.51)
4 Biotech Stocks Poised to Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 3:18PM CDT
Notwithstanding the sector declines, things appear far better now than they did a quarter ago for the biotech sector.
BIIB: 312.00 (+4.95), BMRN: 97.57 (-0.38), GILD: 81.70 (-0.08), AMGN: 173.85 (+0.47), ABBV: 64.10 (+0.82), ARIA: 13.41 (+0.51), AEGN: 18.27 (+0.37)
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Mon Aug 01, 3:02PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib). As a result of the second tranche payment, under the terms of the ARIAD Royalty Agreement, PDL's royalty percentage will increase to 5.0% of the U.S. and European net revenues of Iclusig and 5.0% of the payments ARIAD receives elsewhere in the world until December 31, 2018 (subject to agreed-upon annual maximum payments). Beginning January 1, 2019 and thereafter, the royalty rate will increase to 6.5% in all jurisdictions and continue until December 31, 2033, subject to a put option of PDL upon the occurrence of specified events and a call option of ARIAD.
ARIA: 13.41 (+0.51), PDLI: 3.36 (+0.13)
